FDC Income Statement | StatInvestor

Health Care & Life Sciences » Pharmaceuticals | FDC Ltd.

FDC Ltd. | Income Statement

Fiscal year is April-March. All values INR Millions.

2014

2015

2016

2017

2018

Sales/Revenue

8,389

8,844

9,885

10,079

10,689

Cost of Goods Sold (COGS) incl. D&A

5,205

5,561

6,120

6,224

6,762

Gross Income

3,184

3,283

3,764

3,855

3,928

SG&A Expense

1,411

1,707

1,815

1,765

1,968

EBIT

1,759

1,557

1,950

Unusual Expense

123

247

Non Operating Income/Expense

303

350

256

171

354

Interest Expense

Pretax Income

2,184

2,037

2,326

2,518

2,411

Income Tax

830

555

635

633

671

Equity in Affiliates

Consolidated Net Income

1,353

1,481

1,687

1,885

1,735

Net Income

1,353

1,481

1,687

1,885

1,735

Net Income After Extraordinaries

1,353

1,481

1,687

1,885

1,735

Net Income Available to Common

1,353

1,481

1,687

1,885

1,735

EPS (Basic)

7.59

8.33

9.48

10.60

9.76

Basic Shares Outstanding

178

EPS (Diluted)

7.59

8.33

9.48

10.60

9.76

Diluted Shares Outstanding

178

EBITDA

2,009

1,945

2,243

2,428

2,301

Other Operating Expense

Non-Operating Interest Income

152

147

About FDC

View Profile

Address	142-48, S. V. Road Mumbai Maharashtra 400102 India
Employees	-
Website	http://www.fdcindia.com
Updated	09/14/2018
FDC Ltd. engages in the business of pharmaceutical. It presence in therapeutic segments, such as, anti-infectives, gastrointestinals, ophthalmologicals, vitamins, minerals, dietary supplements, cardiac, anti-diabetes, respiratory, gynaecology, dermatology, analgesics and others. The company products are sold under brand names, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.